Efficacy and safety of adalimumab in Behcet's disease-related uveitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027147

Enrollment

Unknown

Registered

2019-11-02

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet's disease-related uveitis

Interventions

1:Adalimumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Recurrent oral ulcer, more than three times a year;Ocular uveitis; 2. At least one of the following three items is met: 1) genital ulcer: the patient or doctor finds genital ulcer; 2) skin involvement: erythema nodosum; pseudofolliculitis; papule; acne like nodule; 3) positive acupuncture test.

Exclusion criteria

Exclusion criteria: Malignancy or systemic infectious diseases, including hepatitis B or C infection or tuberculosis.

Design outcomes

Primary

Measure	Time frame
vision;anterior uveitis activity;	—

Secondary

Measure	Time frame
Intraocular pressure;Fundus vessels leakage;	—

Countries

China

Contacts

Public ContactWenru Su

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University

suwr3@mail.sysu.edu.cn+86 13570364296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026